


09/600,786

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2001:592302 CAPLUS  
DOCUMENT NUMBER: 135:137336  
TITLE: Anandamide derivatives and their therapeutic applications  
.INVENTOR(S): Raphael, Mechoulam; Yoram, Houminer; Tzviel, Sheskin; Esther, Fride; Joram, Slager  
PATENT ASSIGNEE(S): Yissum Research Development Company, Israel  
SOURCE: Israeli, 21 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IL 113228	A1	19990922	IL 1995-113228	19950403
PRIORITY APPLN. INFO.:			IL 1995-113228	19950403
OTHER SOURCE(S):	MARPAT 135:137336			
GI				



AB Anandamide derivs., such as I [R1 = H, alkyl; R2 = alkyl; R3 = (CH<sub>2</sub>)<sub>m</sub>X, CH(CH<sub>3</sub>)(CH<sub>2</sub>)<sub>m</sub>X, cycloalkyl, benzyl, (CH<sub>2</sub>)<sub>q</sub>NH<sub>2</sub>; X = OH, Me; m, = 0, small integer; n = small integer; q = 1, 3; dashed line = single or double bond ], and their optically active isomers were prepared for their use in anti-inflammatory, antiasthmatic, antiglaucoma, antiemetic and analgetic compns. Thus, anandamide derivative II was prepared via a multistep synthetic sequence starting from arachidonic Me ester, Me iodide and ethanolamine. The prepared anandamide derivs. were tested for their binding to the brain cannabinoid receptor CB1, and their therapeutic use in anti-inflammatory, antiglaucoma and antiasthma medicines.